A LEADING MEDICAL RESEARCH INSTITUTE SPECIALISING IN ALZHEIMER’S DISEASE AND RELATED DEMENTIAS
Alzheimer’s Research Australia
With Professor Vicky Vass, Chief Executive Officer
ORGANISATIONS IN MEDICAL RESEARCH
Filmed in Perth, Western Australia | November 2024
Professor Vicky Vass serves as the Chief Executive Officer of Alzheimer’s Research Australia, which is based in Perth, Western Australia. Australian Health Journal met with Professor Vass to hear of the organisation’s mission to solve the mysteries surrounding Alzheimer’s disease, and focus on detection as the key to their efforts.
Founded in 1993, the organisation now comprises a large research team, a clinical trials division, and an administrative support team. Their aim is to make Alzheimer’s a distant memory through rigorous research.
Their philosophy revolves around operating as one cohesive team, which includes all these parts as well as the board, fostering effective collaboration. Leading this team is Professor Ralph Martins AO, as the Chief Inspector in their mission. He focuses on uncovering pathways for prevention, intervention, and the latest treatments for neurodegenerative diseases.
Among the key studies highlighted by Professor Vass is the blood biomarker study led by Professor Ralph Martins, which aims to develop a cost-effective method for detecting Alzheimer’s through a simple blood test. Currently, detection methods involve multiple scans and intense processes, but this initiative could transform the landscape by making detection more accessible and affordable.
Another study is run by Dr. Prashant Bharadwaj who heads the research on childhood dementia, focusing on providing hope to the youngest patients affected by these debilitating diseases. His work is dedicated to ensuring that children have a future filled with memories rather than loss, striving to find ways to detect and ultimately cure childhood dementia.
The board of Alzheimer’s Research Australia comprises a diverse group of individuals, including academics and those involved in commercial work and aged care. The common goal uniting them is to find a cure for Alzheimer’s disease. Funding for the organisation primarily comes from donations and rely heavily on this support, as they do not receive significant government funding, although they do get some grants for research.
Professor Vass describes Alzheimer’s Research Australia as an incredible place to work, boasting a community akin to a family. Every role within the organisation is respected, contributing to a common goal of making Alzheimer’s a distant memory for future generations.
You Might also like
- 
					
					FULL FEATURE Consumers and communities as agents of health care change and improvementPolicymakers, health administrators and clinicians must learn and embrace new ways to harness the transformative role consumers, community members and carers can play. Conversely, consumers and communities need support, capability and capacity to engage as equals in policy, research, program and service design. This is necessary if are to be less technocratic and realise the vision where all members of society can live the best life possible. 
- 
					
					Making clinical trials participant friendlyClinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective. The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities. 
- 
					
					New option for management of high-risk soft tissue sarcoma of the limbSARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb. 
 
		
		 
					
																				
					 
					
																				
					